Medical facility Loyola University Health System reported on Tuesday the appointment of Ravi Durvasula, MD as chair of the department of medicine of Loyola Medicine and Loyola University Chicago Stritch School of Medicine, replacing J. Paul O'Keefe, MD.
Effective 1 November 2017, Dr Durvasula is responsible for the department of medicine, dedicated to excellence in clinical care, research and education. This department includes 14 divisions: allergy, cardiology, dermatology, endocrinology, gastroenterology, general internal medicine, health services research programme, hematology/oncology, hepatology, hospital medicine, infectious disease, nephrology, pulmonary and critical care medicine and rheumatology.
Most recently, Dr Durvasula has worked as a professor of medicine and infectious diseases and director of the Center for Global Health at the University of New Mexico School of Medicine.
Previously, Dr Durvasula chaired the department of medicine of the New Mexico Veterans Affairs Health Care System, served as chief medical officer of Yale University Health Services as well as held senior leadership positions at Yale University and the Veterans Administration.
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Alvotech reports positive topline results for Xolair biosimilar study
DBV Technologies secures up to USD306.9m to advance Viaskin peanut patch programme
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial
CBC Group acquires UCB's mature neurology and allergy business in China